Pazopanib and Rabeprazole interaction
Pazopanib and Rabeprazole: the Pazopanib prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Pazopanib (VOTRIENT) label · effective 2025-12-16
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents.
Avoid concomitant use of VOTRIENT with gastric acid-reducing agents.
If concomitant administration with a gastric acid-reducing agent cannot be avoided, consider short-acting antacids in place of PPIs and H2-receptor antagonists.
Consider short-acting antacids in place of proton pump inhibitors (PPIs) and H2-receptor antagonists.
Concomitant Use With Gastric Acid-Reducing Agents Concomitant use of VOTRIENT with esomeprazole, a PPI, decreased the exposure of pazopanib.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.